Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.30 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8016482 | 0.81 | SLC1A3 (0.37) | CPB2LMNATSHRNAAACYP1A2 | |
| SCHEMBL7578722 | 0.81 | ALDH1A1 (0.37) | LMNATSHRCYP2C19RAB9AKMT2A | |
| SCHEMBL1538031 | 0.72 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19RAB9AKMT2A | |
| SCHEMBL7573941 | 0.68 | ALDH1A1 (0.33) | LMNATSHRRAB9ANPC1 | |
| SCHEMBL7570704 | 0.67 | ALDH1A1 (0.41) | LMNATSHRCYP2C19RAB9AKMT2A | |
| SCHEMBL7573938 | 0.66 | MEN1 (0.37) | LMNAKMT2ATDP1 | |
| SCHEMBL4772634 | 0.66 | CYP1A2 (0.49) | CYP1A2CYP2C9CYP2C19RAB9AKMT2A | |
| SCHEMBL28023546 | 0.65 | POLB (0.49) | CYP1A2CYP2C9CYP2C19RAB9AKMT2A | |
| SCHEMBL7578532 | 0.64 | LMNA (0.32) | LMNA | |
| SCHEMBL9200148 | 0.64 | TP53 (0.39) | LMNATSHRCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198382-A1 | Oxiran carboxylic acids for the treatment of diabetes | HORST P.O. WOLF (DE) | 2002-12-26 | — | — | US | disclosed |
| US-6013666-A | ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION | Jew, Sang Sup (KR) | 2000-01-11 | — | — | US | disclosed |
| WO-1998000422-A1 | OXIRANE CARBOXYLIC ACID DERIVATIVE AND ITS MANUFACTURING METHOD | JEW SANG SUP (KR) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198382-A1 | Oxiran carboxylic acids for the treatment of diabetes | GPR119, SLC5A2, SLC2A4 | CPB2 2185/4885LMNA 3609/4885TSHR 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.